Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML
European Journal of Internal Medicine , 11/06/09
Boehm A et al. – Rapamycin at 2mg per day acts mildly cytoreductive in a subgroup of patients with refractory AML. Higher doses and drug combinations may be required to obtain long lasting anti–leukemic effects in these patients.
Related Articles
Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients
Journal of Dermatological Science, 10/06/09
Relevance Score: 91%
Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs
Nephrology Dialysis Transplantation, 11/17/09
Relevance Score: 89%
Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis
International Journal of Cancer, 11/10/09
Relevance Score: 88%
MYC Activity Mitigates Response to Rapamycin in Prostate Cancer through Eukaryotic Initiation Factor 4E–Binding Protein 1–Mediated Inhibition of Autophagy
Cancer Research, 10/06/09
Relevance Score: 87%
Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors
Pediatric Blood & Cancer, 10/30/09
Relevance Score: 83%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome
Diabetes Care, 11/25/09
Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/25/09
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


